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Background: Previous studies reported that bare metal stents (BMS) restenosis was relatively benign event. However, the outcome of patients with 
target lesion revascularization (TLR) after sirolimus-eluting stents (SES) implantation remains unknown.
Methods: Design of j-CYPHER registry was multi-center prospective enrollment of consecutive patients receiving SES implantation in Japan. From 
August 2004 to November 2006, 12812 patients with 17545 lesions were implanted with SES. Among 10778 patients treated with only SES, we 
divided 7732 patients who were event-free (no death, MI or stroke) at 12 months after SES implantation into 2 groups by TLR. We performed a 12 
months landmark analysis and evaluated the impact of TLR on the combined major adverse event occurred in the next 12 months (13-24 months).
Results: 538 patients (7.0%) had TLR within initial 12 months after SES implantation. Landmark analysis revealed that the rates of combined 
major adverse event, death, MI and stroke occurred in the next 12 months were 7.4%, 5.8%, 0.7% and 1.5%, respectively. In 7194 patients without 
TLR, they were 4.4%, 2.8%, 0.6% and 1.3%, respectively. Several variables listed in the table showed significant correlation (P< 0.05) with the 
combined major adverse event in univariate analysis. In multiple logistic regression analysis, TLR was not associated with the combined major 
adverse event (OR 1.74, 95%CI 0.80-1.75, P=0.4).
Conclusion: SES restenosis was also relatively benign event in our study population.
